Collaborations and Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2023	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Costs to obtain or fulfill contract capitalized		$ 0
Collaboration revenue		16,627,000	$ 28,935,000
Deferred revenue		33,822,000	55,624,000	$ 38,917,000	$ 60,993,000
Accrued expenses		40,805,000		55,355,000
Regeneron Pharmaceuticals Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate transaction price remaining to be recognized		21,300,000
Deferred revenue		21,300,000		26,400,000
Regeneron Pharmaceuticals Inc. [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable		9,200,000		7,200,000
Regeneron Pharmaceuticals Inc. [Member] | Hemophilia Co Co Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		100,000	3,300,000
Reimbursements cost		1,500,000
Regeneron Pharmaceuticals Inc. [Member] | Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		7,000,000	4,700,000
Deferred revenue	$ 30,000,000
Collaboration agreement further option extension period	two years
Collaboration term extension period	2026-04
Regeneron Pharmaceuticals Inc. [Member] | Two Thousand Sixteen Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		5,100,000	5,200,000
Regeneron Pharmaceuticals Inc. [Member] | Two Thousand Twenty Three Regeneron Amendment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		100,000	600,000
Regeneron Pharmaceuticals Inc. [Member] | Variable Consideration [Member] | Two Thousand Sixteen Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		1,800,000
Sparing Vision [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		0	500,000
Deferred revenue		12,500,000		12,500,000
Sparing Vision [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable		200,000		600,000
AvenCell [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		21,000,000	21,000,000
Accounts receivable		1,000,000		700,000
Accrued expenses		1,000,000		$ 1,000,000
AvenCell [Member] | Research Materials Shippmet Services [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		1,000,000
Kyverna Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		0	0
ONK Therapeutics [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 0	$ 0